Dr. Jose Mario Pimiento, MD

Dr. Pimiento practices at H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida.

Dr. Pimiento's NPI, 1063670487, was assigned on June 2, 2008. Dr. Pimiento graduated from National University of Colombia in 2000. Dr. Pimiento's Michigan license number on file is 4301101914.

Dr. Pimiento's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD, at 10901 McKinley Dr, Tampa, FL 33612.

Dr. Pimiento's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida. Dr. Pimiento is also affiliated with Moffitt Cancer Hospital. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Pimiento to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Pimiento practices, 3 sites in all. Vendor and product names are available with a free account.

Surgery is Dr. Pimiento's primary specialty in the NPI Registry, under taxonomy code 208600000X. Dr. Pimiento is board certified in surgery by the American Board of Surgery. Dmand AI has Dr. Pimiento's licenses on file in 2 states: Michigan and Florida.

Dmand AI lists colon removal, esophagus, stomach, or upper small intestine surgery, gallbladder removal and gastrointestinal obstruction among the conditions Dr. Pimiento treats.

CMS data shows 174 Medicare services from Dr. Pimiento across 6 procedure codes in 2024, for 119 Medicare patients. Medicare paid $10,916 for them.

CMS counts 119 Medicare patients who saw Dr. Pimiento in 2024. The largest group is 65 to 74, with 57 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.88, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Pimiento's median patient age at 69, with 37% women.

In 2024, Dr. Pimiento wrote 71 Medicare Part D claims for 36 patients. 82% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $142 in total drug cost. In 2020, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Pimiento for performance year 2024, reported as part of a group. Dr. Pimiento accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Pimiento as offering telehealth. CMS counts 32 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. Pimiento, more than 56% of the clinicians it reports for that procedure.

Dmand AI links 105 papers to Dr. Pimiento, published from 2006 to 2025. 2021 was the busiest year, with 10. The most frequent topics are Adenocarcinoma, Esophageal Neoplasms and Stomach Neoplasms. Dr. Pimiento has published most often in Ann Surg Oncol. Dr. Pimiento's most frequent co-authors are Mokenge P. Malafa, MD, Sarah Elizabeth Hoffe, MD and Pamela J. Hodul, MD.

CMS Open Payments shows 35 general payments to Dr. Pimiento from 13 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 89% of the total. Medical Device Business Services, Inc. paid the most, $15,038. It also lists 1 research payment totaling $595 in 2016.

Dmand AI lists 2 awards for Dr. Pimiento, most recently Dudrick research scholar in 2019.

Dr. Pimiento graduated from National University of Colombia in 2000. Dr. Pimiento is a member of ACS, AAS, SAGES and SSO.

Dr. Pimiento is in network with 10 carriers, including Elevance, Excellus BlueCross BlueShield and United Healthcare. HMO plans come from the most carriers, 7. Check the plan with the practice before a visit.